Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd. et al.

I'll research this case to build an accurate overview.

Let me dig into the MDL, the IPR proceedings, and the drug's market context.

Now let me verify Torrent's corporate profile and the market context, plus any publicly reported settlement terms.

Case Overview: Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd., No. 1:19-cv-00320-RGA (D. Del.)

Parties and accused product. Plaintiff Merck Sharp & Dohme Corp. (now Merck Sharp & Dohme LLC) is the operating-company innovator arm of Merck & Co., Inc. — not an NPE/PAE; Stanford's NPE Litigation Database classifies Merck in this litigation as a "Product company," and the assertion is a classic branded-vs.-generic Hatch-Waxman action. Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. are, respectively, the Ahmedabad, India–headquartered generic manufacturer (founded 1959 as Trinity Laboratories, a Torrent Group flagship) and its U.S. subsidiary, which the complaints in related Torrent matters describe as a single integrated enterprise for ANDA approval and U.S. commercialization. The accused conduct is Torrent's submission of ANDA No. 212920 seeking FDA approval to market a generic sitagliptin phosphate product (the active ingredient in Merck's JANUVIA® franchise) with a Paragraph IV certification against the asserted patent. The docket does not publicly identify whether ANDA 212920 covers a sitagliptin-only tablet or a sitagliptin/metformin combination product; the consent judgment merely defines the "Torrent Product" by reference to that ANDA and to confidential settlement terms (D.I. 45, 46).

Patent asserted. The sole patent asserted against Torrent is U.S. Patent No. 7,326,708 ("Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor," granted Feb. 5, 2008; priority June 24, 2003). In one line: the '708 patent claims the dihydrogenphosphate (DHP) salt of sitagliptin — specifically the crystalline monohydrate of the 1:1 sitagliptin DHP salt (claims 1–4) and a process for crystallizing it from isopropanol/water (claim 24), the salt form actually marketed in JANUVIA®. The '708 patent was the only patent Merck asserted against Torrent; in the umbrella MDL, Merck also asserted U.S. Patent No. 8,414,921 (pharmaceutical compositions of sitagliptin DHP plus metformin, i.e., the JANUMET® line) against a subset of defendants, but not Torrent. The Orange Book lists the '708 patent for JANUVIA/JANUMET/JANUMET XR with a stated expiry of November 24, 2026, plus six months' pediatric exclusivity to May 24, 2027 — i.e., a term well beyond the nominal 20-year date, reflecting a patent term extension.

Posture, venue, and why it matters. Merck filed this action on February 13, 2019, in the U.S. District Court for the District of Delaware, assigned to Judge Richard G. Andrews (Wilmington) — the nation's busiest Hatch-Waxman venue, and the district where the U.S. subsidiary is incorporated and registered to do business. This case became one of fourteen actions (thirteen in Delaware plus Merck v. Mylan in N.D. W. Va.) that the Judicial Panel on Multidistrict Litigation centralized on July 19, 2019 as In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 2902, before Judge Andrews; the JPML noted Merck filed after generic manufacturers submitted a total of 26 ANDAs for generic sitagliptin, and selected Delaware because thirteen of the fourteen cases were already there and Judge Andrews was "well-versed in complex patent litigation." Torrent's answer deadline was extended to May 6, 2019 (D.I. 9), and the case was resolved early: the parties filed a proposed consent judgment on February 18, 2020, entered by Judge Andrews on February 19, 2020 (D.I. 46), permanently enjoining Torrent from making, using, selling, or importing the Torrent Product, with all claims and counterclaims dismissed with prejudice (D.I. 45, 46; patent report to the Commissioner filed Feb. 20, 2020). The commercial terms — including any licensed generic entry date — are in confidential settlement agreements and are not publicly disclosed in the docket materials.

The case is notable for several reasons. First, market context: sitagliptin (JANUVIA/JANUMET/JANUMET XR/JUVISYNC/STEGLUJAN) was one of the largest-selling oral Type 2 diabetes franchises in the world, making the MDL a multi-billion-dollar referential Hatch-Waxman cluster rather than an isolated suit. Second, it is an IPR-linkage case: Mylan's IPR2020-00040 (petition filed Oct. 30, 2019; instituted May 12, 2020) challenged claims 1–4, 17, 19, 21–23 of the '708 patent, with Dr. Reddy's joined in IPR2020-01060 and Sun Pharmaceutical joined in IPR2020-01072 (a separate Teva petition, IPR2020-01045, is also on record). The Board's Final Written Decision of May 7, 2021 held no challenged claim unpatentable, rejecting both express and inherent anticipation by Merck's own earlier WO 03/004498/Edmondson art and rejecting obviousness (Merck antedated the art under pre-AIA § 102(a), and commonly-owned § 102(e) art was disqualified under § 103(c)(1)); the Federal Circuit affirmed in Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., No. 21-2121 (Fed. Cir. Oct. 2022) (Lourie, J.), on substantial-evidence review, distinguishing In re Petering because the asserted genus of "957 salts" was not a "limited class." That affirmance effectively insulated the '708 patent and drove the wave of MDL settlements (Torrent in Feb. 2020, Dr. Reddy's in Oct. 2021, and others). Third, it illustrates the post-settlement enforcement tail: Merck has continued to assert the '708 patent in follow-on ANDA suits (e.g., v. Prinston, 1:22-cv-01071; v. Laurus Labs, 1:22-cv-01348; v. Azurity, 1:24-cv-00545, dismissed without prejudice in 2024; v. Aurobindo, 1:25-cv-00449), and Torrent continues to appear as a defendant in sitagliptin-family and other Merck/Bayer Delaware litigations.

---

Caveats on sourcing: The docket entries, MDL transfer order, Markman opinion (In re Sitagliptin, 19-md-2902, D.I. 135 in 19-cv-311, Nov. 17, 2020), PTAB FWD, and Federal Circuit affirmance are verified from public records. The specific terms and timing of Torrent's licensed generic entry are sealed. My description of Torrent's corporate structure relies on pleading allegations in related Docket materials rather than an audited corporate record, and I have not independently verified current Januvia franchise revenue figures for FY2019, so I have avoided stating a dollar amount.

I'll research this case systematically across multiple sources.

Let me dig into the docket and related proceedings.

Now let me get the full docket detail and IPR information.

I'll research the docket and counsel of record for the plaintiff in this case.

I have strong leads. Let me verify the docket entries and attorney details further.

Let me confirm the specific docket entries and lead-counsel designations.

Counsel of Record for Plaintiff Merck Sharp & Dohme Corp.

Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd. & Torrent Pharma Inc., C.A. No. 1:19-cv-00320-RGA (D. Del.) — In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902-RGA

There is no in-house Merck attorney on the docket; Merck was represented by a two-firm team: McCarter & English LLP (Delaware counsel of record, all papers filed under Local Rule 83.5(d)) and Williams & Connolly LLP (Washington, D.C., lead trial/outside counsel, admitted pro hac vice). Nothing here is sealed in a way that hides counsel — the appearances below are drawn from the public docket and docketed filings (CourtListener docket 14627874; Justia docket).

---

1. Delaware counsel of record — McCarter & English, LLP (Renaissance Centre, 405 N. King St., 8th Fl., Wilmington, DE 19801)

2. Lead trial / outside counsel — Williams & Connolly LLP (725 Twelfth St., N.W., Washington, DC 20005)

These attorneys were moved in by the February 21, 2019 pro hac vice motion (docketed as DE 6 in the coordinated Delaware complaints; SO ORDERED by Judge Andrews Feb. 22, 2019), and appear on the Consent Judgment signature block and the Rule 7.1/ANDA supplemental-information filings. The complaint's ANDA cover sheet listed them as "OF COUNSEL."

---

Procedural posture and sourcing notes

• Appearances (CM/ECF "attorney to be noticed" list for 1:19-cv-00320): Jingyuan Luo, Anthony H. Sheh, Michael P. Kelly, Daniel M. Silver, Alexandra M. Joyce — per Justia and UniCourt. Genderson, Berniker, Fisher, Mahaffy and Zolan appear through the PHV motion/order and the Consent Judgment rather than on the 19-320 noticing list; the consolidated MDL docket (19-md-2902-RGA) carries the full roster with Kelly as "LEAD ATTORNEY."
• Termination: Consent Judgment entered Feb. 19, 2020 (order granting DE 45; docketed DE 63), dismissing all claims and counterclaims with prejudice; Torrent's ANDA No. 212,920 product enjoined under the '708 patent. Case terminated 2/19/2020.
• Caution on one document: The Consent Judgment PDF ([ded

I'll research the docket and counsel of record for the Torrent defendants in this D. Del. action.

I have the core picture. Let me verify the answer/counterclaim signature blocks and research the individual attorneys' backgrounds.

Counsel of Record for Defendants — Torrent Pharmaceuticals Ltd. & Torrent Pharma Inc.

Case: Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd. et al., No. 1:19-cv-00320-RGA (D. Del., filed Feb. 13, 2019; consent judgment entered Feb. 19, 2020). Judge Richard G. Andrews.

This was an ANDA/Hatch-Waxman action over U.S. Patent 7,326,708 (sitagliptin phosphate), later coordinated into In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, No. 19-md-2902-RGA. Torrent was represented by a two-firm team: a Wilmington local-counsel firm and a Washington, DC–based national patent litigation firm appearing pro hac vice.

---

Local counsel (Delaware) — Abrams & Bayliss LLP

John M. Seaman (#3868) — Local counsel / Delaware counsel of record

• Abrams & Bayliss LLP, 20 Montchanin Road, Suite 200, Wilmington, DE 19807; (302) 778-1000; seaman@abramsbayliss.com
• Signed the first defense filings in the case: the Stipulation to Extend Time (D.I. 9, Mar. 6, 2019), the motion for pro hac vice admission of the Wiley attorneys (D.I. 10, Mar. 19, 2019), and Defendants' Answer, Defenses, and Counterclaims (D.I. 12, May 6, 2019). Also listed on the consent judgment signature block.
• D. Del. local-rule counsel (LR 83.5(d)) — the registered CM/ECF filer for the defense. (Note: I could not independently verify his individual patent-case track record from a firm bio page within this search; the docket itself is the source for his role.)

April M. Kirby (#6152) — Local counsel

• Same firm/address; akirby@abramsbayliss.com
• Signed the proposed Consent Judgment on behalf of Torrent (D.I. 45, Feb. 18, 2020) alongside Seaman. Also appears in the joint invalidity-contentions service list for the coordinated MDL.

Lead / outside counsel — Wiley Rein LLP (now "Wiley"), Washington, DC

A. Neal Seth — Lead counsel (admitted pro hac vice)

• Wiley Rein LLP, 1776 K Street NW, Washington, DC 20006; (202) 719-4356; nseth@wiley.law (also uses wileyrein.com)
• Named as Torrent's outside patent counsel in the PHV motion (D.I. 10, certifying him under D. Del. LR 83.5(d)); PHV appearance noted on the docket Apr. 2, 2019. Sits in the defense signature block of the consent judgment.
• Experience: Registered patent attorney (Reg. No. 67,075) with a chemical-engineering background (B.S., Cornell; J.D., George Washington). He leads Wiley's patent litigation practice and is a career Hatch-Waxman/ANDA litigator; Wiley's 2014 announcement of his hire notes he "has served as lead counsel in defending against claims of patent infringement in the manufacturing and pharmaceutical sectors," and a 2016 firm release credits him with leading matters on aripiprazole (Abilify), bendamustine (Treanda), fesoterodine (Toviaz), and roflumilast (Daliresp). Named to Bisnow's "Top 40 Lawyers Under 40" (2016). He also served as counsel in IPR proceedings (e.g., a Dec. 2019 patent-owner submission listing him at Wiley Rein). Caveat: he has since moved on from Wiley (he is now at Woods Rogers Vandeventer Black in Tysons, VA, per a May 2026 announcement), so he was Wiley counsel at the time of this case.

Laura R. Braden — Of counsel / supporting counsel (admitted pro hac vice)

• Wiley Rein LLP, 1776 K Street NW, Washington, DC 20006; (202) 719-4356; lbraden@wiley.law
• Named in the same PHV motion (D.I. 10); PHV appearance docketed Mar. 22, 2019 (the docket entry appears in associated cases, including a Macleods matter). Listed in the defense signature block of the consent judgment.
• Experience: Her Law360 attorney profile lists a pharmaceutical product-liability matter (Johnson v. Novartis, W.D. Tex., 2019); I did not find a detailed firm bio confirming a broader ANDA track record, so I'd treat her role as supporting counsel on this team rather than independently verified Hatch-Waxman lead experience.

Plaintiff's counsel (for contrast — not your question)

Merck was represented by McCarter & English LLP (Michael P. Kelly, Daniel M. Silver, Alexandra M. Joyce; Wilmington, DE) as local counsel and Williams & Connolly LLP (Bruce R. Genderson, Jessamyn S. Berniker, Stanley E. Fisher, Alexander S. Zolan, Shaun P. Mahaffy, Anthony H. Sheh, Jingyuan Luo; Washington, DC) as lead counsel.

---

Sourcing, gaps, and cautions

• Authoritative sources used: the D. Del. docket entries for this case (D.I. 9, 10, 12, 43, 45) and the proposed Consent Judgment (D.I. 45) with its merged caption for In re Sitagliptin Phosphate, No. 19-md-2902-RGA — CourtListener docket 14627874; D.I. 45 PDF; Justia docket.
• No in-house counsel appeared on this docket — the only appearances/pro hac vice admissions for Torrent were Seaman and Kirby (Abrams & Bayliss) and Seth and Braden (Wiley Rein). Torrent's litigation was run by outside counsel.
• Nothing appears sealed as to counsel identity; the filings here are public. The case settled (consent judgment, D.I. 45, entered Feb. 19, 2020; case terminated Feb. 19, 2020), so no trial counsel after that point.
• Do not conflate with other Torrent matters. Torrent used different counsel in other litigations (e.g., Kirkland & Ellis in the valsartan MDL; Pergament & Cepeda / Smith Katzenstein in a Hetero-co-defended case; and Phillips, McLaughlin & Hall in a later, unrelated Adverio Pharma/Bayer/MSD v. Torrent action). Those appearances are not counsel of record in 1:19-cv-00320.
• Firm name note: Wiley Rein LLP rebranded to "Wiley" in 2022, hence the filings showing "WILEY" with wiley.law addresses while the PHV motion (2019) says "Wiley Rein LLP."
• Verification limits: I could not pull a firm bio page for John M. Seaman or April M. Kirby or a full bio for Laura R. Braden within this search; their roles above are grounded in the docket/signature blocks rather than in independently sourced experience descriptions. Everything attributed to A. Neal Seth's experience comes from Wiley press releases and third-party profiles, which I've cited.